Contact Us
Plans and Services Health and Wellness About Wellmark Member Employer Producer Provider
Home Provider Medical Policies and Authorizations Alphabetical Listing

» Working with
» News
» BlueCard®
» Claims and Payment
» Medical Policies and Authorizations
» Health Management
» Medical, Dental, and Pharmacy
» Credentialing and Contracting
» Quality and Transparency
» Communications and Resources
» Health Care Reform for Providers
printer friendly Printer-Friendly Page

Subcutaneous ICD

» Summary» Procedure Codes
» Description» Selected References
» Prior Approval» Policy History
» Policy

Medical Policy: 02.02.16 
Original Effective Date: July 2013 
Reviewed: September 2015 
Revised: September 2015 

Benefit Application
Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.


The automatic implantable cardioverter defibrillator (ICD) is a device designed to monitor a patient's heart rate, recognize ventricular fibrillation (VF) or ventricular tachycardia (VT), and deliver an electric shock to terminate these arrhythmias to reduce the risk of sudden death.


Indications for ICD implantation can be broadly subdivided into 1) secondary prevention, i.e., their use in patients who have experienced a potentially life-threatening episode of ventricular tachyarrhythmia (VT) (near sudden cardiac death); and 2) primary prevention, i.e., their use in patients who are considered at high risk for sudden cardiac death but who have not yet experienced life-threatening VT or ventricular fibrillation (VF).


A totally subcutaneous ICD (S-ICD®) has been developed. This device does not employ transvenous leads and thus avoids the need for venous access and complications associated with the venous leads. Rather, the S-ICD® uses a subcutaneous electrode that is implanted adjacent to the left sternum. The electrodes sense the cardiac rhythm and deliver countershocks through the subcutaneous tissue of the chest wall.


On September 28, 2012, the S-ICD® system by Cameron Health, Inc. was approved by the FDA "to provide defibrillation therapy for the treatment of life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic bradycardia, continual (incessant) ventricular tachycardia, or spontaneous frequently recurring ventricular tachycardia that is reliably terminated with anti-tachycardia pacing".  Boston Scientific Corp. announced on March 17, 2015, that it received U.S. Food and Drug Administration approval, as well as the CE mark, for its Emblem™ S-ICD system. The Emblem is the next-generation S-ICD. According to the company, the Emblem device is 20% thinner than the S-ICD, and its battery will last 40% longer. The device is also enabled for remote patient management through the Latitude™ NXT Patient Management System.


As part of the S-ICD's 2012 marketing approval, FDA required Boston Scientific to conduct a 5-year, 1,600-patient postmarket study to assess long-term safety and performance, as well as possible differences in effectiveness between genders. That study is currently recruiting participants and has an estimated completion date of 2020. The RCT will study the efficacy and adverse effects of the subcutaneous and transvenous ICD in individuals with a Class I or IIa indication for ICD without an indication for pacing. Several other clinical trials are ongoing.


The first study on outcomes of an entirely subcutaneous ICD was published in 2010. This study described the development and testing of the device, including empiric evidence for the optimal placement of the subcutaneous electrode.


National Institute for Health and Care Excellence (NICE) published guidance in April 2013 on the insertion of a subcutaneous implantable defibrillator with the following guidance: Current evidence on the efficacy of the insertion of a subcutaneous implantable cardioverter defibrillator (ICD) for the prevention of sudden cardiac death in the short and medium term is adequate. Evidence on its safety in the short term is adequate but there are uncertainties about long-term durability. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research.


A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance published in 2013 regarding the subcutaneous ICD stated: further study is necessary to determine whether benefits might outweigh risks in patients who currently appear to derive little benefit from ICD therapy due to comorbidities and competing mortality risks.


In a subcommittee of the European Society of Cardiology the following was reported:

Reported advantages and disadvantages of the S-ICD® system:

The advantages of the S-ICD are:

  1. The absence of leads within the heart and the preservation of central venous circulation is the main advantage making it a great alternative for children with congenital heart diseases or patients with no venous access who were unsuitable for transvenous ICD.
  2. There is no risk of vascular injury or pneumothorax.
  3. The risk of systemic infections appears to be very low, best in high risk cases of previous device infection, hemodialysis, chronic immunosuppression therapy immunodeficiencies, or artificial heart valves.
  4. Although pocket infections can occur with the S-ICD (5-10%, similar to transvenous devices) infection resolves with antibiotics in the majority of cases.
  5. Explantation is rarely necessary however explanting an S-ICD is much simpler and safer than endovascular lead extraction. Young patients with high lead failure rates due to an active lifestyle may especially benefit.
  6. The simplified implant procedure, with no need for fluoroscopy favors a more widespread use of a life-saving therapy, even in those centers without great experience in traditional surgical procedure, with less risk of serious complications.
  7. The S-ICD has cosmetic advantages despite its larger size, owing to the anatomic location in the lateral axilla: this location, rather than the anterior infraclavicular position is particularly appreciated by women.
  8. The device is well tolerated, no explantation due to patient discomfort has been noted.
  9. Another benefit is the lack of apparent myocardial damage despite greater shock intensity (80 J). Energy is actually distributed more evenly throughout the myocardium, with only 10% of delivered energy reaching cardiac myocytes: elevation of serum bio-markers of myocardial damage is lessened, and this may be particularly important in patients with ventricular dysfunction.

Described further are the limitations of the device:

  1. Pre-implantation screening is mandatory. Using a customised transparent plastic tool provided by the manufacturer, a modified “ad hoc” ECG skin electrode positioning is carried out to verify adequate sensing of subcutaneous signals, avoiding double counting of QRS or T wave oversensing (TWOS) in particular. Up to 7.4% of possible candidates would not be suitable for implant: hypertrophic cardiomyopathy, heavy weight, prolonged QRS duration and a R/T ratio <3 were independently associated with screening failure.
  2. Rates of inappropriate shocks are similar to those occuring with the transvenous ICD and range from 4 to 25% however the mechanisms are different. WIth the S-ICD, eighty per cent of inappropriate shocks are caused by TWOS, especially in congenital heart disease, Brugada and long QT syndromes, while in transvenous ICD, TWOS is involved in about 20% of cases. Accurate screening is possible even with acquisition of templates during exercise. Moreover about 5 to 10% of inappropriate shocks can be caused by muscular noise due to myopotentials (lead is placed over intercostal and pectoral muscles) but this problem may be overcome by reprogramming the sensing vector. Explantation can become necessary (5% in one study) when repeated shocks due to TWOS or noise occur despite different vectors programming.
  3. The risk for undersensing of true arrhythmias (i.e. VF with very low amplitude waves)
  4. Prolonged time to therapy compared with transvenous ICD (14-18” vs 7-8”)
  5. Inadequate shock efficacy on spontaneous clinical VT/VF (22). Indeed, there are still relatively few data regarding long term performance of the S-ICD in a “real world” scenario therefore larger experience and longer follow-up are required, nevertheless initial results are encouraging (no death can be attributed to device or lead failure in published studies).
  6. Other limitations are no pacing capability (with the exception of post-shock pacing) that also means no ATP nor resynchronisation therapy delivery (CRT).
  7. Remote monitoring and atrial tachyarrhythmias monitoring are not yet available.
  8. Pulse generator is larger, with anticipated life battery shorter than traditional devices (about 5 years).
  9. Costs are still high: The S-ICD cost is 4-6x than that of a single chamber transvenous ICD.


Prior Approval: 


Not Applicable



The use of a subcutaneous ICD is considered investigational for all indications in adult and pediatric patients.


At the present time, there is insufficient published data regarding the safety, efficacy and long-term outcomes from use of the S-ICD System, and further study is needed to confirm its usefulness as an alternative to conventional transvenous ICD devices.  The results from ongoing clinical studies will determine the S-ICD system's long-term performance, and better define suitable patient profiles.


Procedure Codes and Billing Guidelines: 

  • To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or diagnosis codes.
  • 33270 Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters, when performed
  • 33271 Insertion of subcutaneous implantable defibrillator electrode
  • 33272 Removal of subcutaneous implantable defibrillator electrode
  • 33273 Repositioning of previously implanted subcutaneous implantable defibrillator electrode
  • 93260 Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; implantable subcutaneous lead defibrillator system
  • 93261 Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable subcutaneous lead defibrillator system
  • 93644 Electrophysiologic evaluation of subcutaneous implantable defibrillator (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)


Selected References: 

Wellmark's policy is based on:

  • Bardy GH, Smith WM, Hood MA et al. An entirely subcutaneous implantable cardioverter-defibrillator. N. Engl. J. Med. 2010; 363(1):36-44.
  • Gold MR, Theuns DA, Knight BP et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J. Cardiovasc. Electrophysiol. 2012; 23(4):359-66.
  • Jarman JW, Lascelles K, Wong T, Markides V, Clague JR, Till J: Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: Cause for caution. Eur Heart J 2012;33:1351-1359
  • Pedersen SS, Lambiase P, Boersma LV, Murgatroyd F, Johansen JB, Reeve H, Stuart AG, Adragao P, Theuns DA: Evaluation of factors impacting clinical outcome and cost effectiveness of the S-ICD: Design and rationale of the EFFORTLESS S-ICD Registry. Pacing Clin Electrophysiol 2012;35:574-579
  • Blue Cross and Blue Shield Association Medical Policy Reference Manual Issue 5:2013. Accessed 6/18/13.
  • Lambiase PD, Barr C, Theuns DA et al. Worldwide experience with totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD registry. Eur Heart J 2014;doi:10.1093/eurheartj/ehu112.
  • Jarman JW, Todd DM. United Kingdom national experience of entirely subcutaneous implantablecardioverter-defibrillator technology: important lessons to learn. Europace 2013;15:1158-1165.
  • NICE Interventional Procedures Guidance [IPG454}]. Insertion of a subcutaneous implantable cardioverter defibrillator for prevention of sudden cardiac death. 24 April 2013.
  • Who Should Receive the Subcutaneous Implanted Defibrillator? The Subcutaneous Implantable Cardioverter Defibrillator (ICD) Should Be Considered in all ICD Patients Who Do Not Require Pacing. Poole JE, Gold MR. Circ Arrhythm Electrophysiol. 2013 Dec 1;6(6):1236-45.
  • Evaluation of acute cardiac and chest wall damage after shocks with a subcutaneous implantable cardioverter defibrillator in Swine. Killingsworth CR, Melnick SB, Litovsky SH, Ideker RE, Walcott GP. Pacing Clin Electrophysiol. 2013 Oct;36(10):1265-72.
  • Which Patients Are Not Suitable for a Subcutaneous ICD: Incidence and Predictors of Failed QRS-T-Wave Morphology Screening. Olde Nordkamp LR, Warnaars JL, Kooiman KM, de Groot JR, Rosenmöller BR, Wilde AA, Knops RE. J Cardiovasc Electrophysiol. 2013 Dec 9. doi: 10.1111/jce.12343. [Epub ahead of print].
  • Who should receive the subcutaneous implanted defibrillator? Timing is not right to replace the transvenous implantable cardioverter defibrillator.  Acha MR, Milan D. Circ Arrhythm Electrophysiol. 2013 Dec 1;6(6):1246-51.
  • Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD: design and rationale of the EFFORTLESS S-ICD Registry. Pedersen SS, Lambiase P, Boersma LV, Murgatroyd F, Johansen JB, Reeve H, Stuart AG, Adragao P, Theuns DA. Pacing Clin Electrophysiol. 2012 May;35(5):574-9.
  • Maria ED, Olaru A., Cappelli S. The subcutaneous defibrillator: who stands to benefit. An article from the e-journal of the ESC Council for Cardiology. Vol 12 No17, 04Mar2014.


Policy History: 

Date                                 Reason                      Action
July 2013                           New Policy                 New Policy

December 2013                 Annual review              Policy renewed

October 2014                    Annual review              Policy revised

September 2015               Annual review               Policy revised


Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc.   They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.

*Current Procedural Terminology © 2012 American Medical Association. All Rights Reserved.

Contact Information
New information or technology that would be relevant for Wellmark to consider when this policy is next reviewed may be submitted to:
  Wellmark Blue Cross and Blue Shield
  Medical Policy Analyst
  P.O. Box 9232
  Des Moines, IA 50306-9232
FacebookTwitterInstagrampinterestLinked InYou Tube